Posts

Showing posts from May, 2024

Tradjenta side effects: What you should know

Image
Tradjenta (linagliptin) is a brand-name prescription medication. It’s approved by the Food and Drug Administration (FDA) to improve   Blood sugar levels   in adults with   T ype 2 diabetes . Tradjenta is typically used as a long-term treatment. Here are some fast facts about Tradjenta: Active ingredient:  linagliptin Drug class:  dipeptidyl peptidase-4 (DPP-4) inhibitor Drug strength:  5 milligrams (mg) Drug form:  oral tablets Like other drugs, Tradjenta can cause side effects. Read on to learn about potential common, mild, and serious side effects.  More common side effects of Tradjenta Tradjenta can cause certain adverse effects (side effects), some of which are more common than others.  These side effects may be temporary, lasting a few days to weeks.  But if the side effects last longer than that, bother you, or become severe, be sure to talk with your doctor or pharmacist. These are just a few of the more common side effects repor...

What is Forxiga used to treat?

Image
Forxiga ( Dapagliflozin) 5 Mg is a Tablet manufactured by Astra Zeneca. It is commonly used for the diagnosis or Treatment of Type 2 diabetes . It has some side effects such as Frequent urge to urinate, Dizziness, Fall in blood sugar level, Urinary tract infection. The salts Dapagliflozin are involved in the preparation of Forxiga ( Dapagliflozin) 5 Mg. Forxiga 5mg Tablet is an antidiabetic drug in the category of sodium-glucose cotransport-2 (SGLT-2)   inhibitors, containing the active ingredient Dapagliflozin. It mainly treats type 2 diabetes mellitus in patients above 18 years and older. Diabetes mellitus is a chronic metabolic disease characterized by increased blood sugar levels (hyperglycemia). This drug is also approved for treating heart failure with reduced ejection fraction (HFrEF) in adults. It helps to improve symptoms and reduce the risk of hospitalization for heart failure. This drug mainly helps to control high blood glucose (sugar) levels in individuals with type 2...